Recent 8-K filings for XBP
Highest-materiality recent filing
XBP Global Q2 revenue up 17.8% YoY, completes BPA acquisition eliminating $1.1B debt
- Q2 revenue $39.6M (+17.8% YoY); gross margin 29.8% (+1020 bps); Adj. EBITDA $3.3M (+173.8% YoY).
- Net loss from continuing ops $3.4M vs $3.6M YoY; operating loss $1.6M.
-
XBP Global Q1 revenue down 14.2% to $197.1M, net loss $26.8M; Board launches strategic review
Revenue $197.1M, pro forma decline 14.2% YoY; Net loss $26.8M.
-
XBP Global Q4 revenue falls 15.1% pro forma; full-year GAAP net income $1.1B on acquisition
Full-year reported revenue $791.0M, down 9.4% YoY; pro forma revenue $879.6M, down 13.6%.
-
XBP Global amends ABL credit agreement; eliminates $7.5M excess availability covenant
Third Amendment to ABL Credit Agreement dated March 6, 2026 eliminates minimum excess availability of $7.5M.
-
XBP Global reports Q3 revenue $209.1M, down 10.4% YoY; pro forma EBITDA up 7.4%
As-reported revenue $209.1M, -10.4% YoY; pro forma revenue $220.4M, -18.1%.
-
XBP Global receives Nasdaq bid-price deficiency notice; 180-day cure period
Company received Nasdaq notice on Sept 16, 2025 due to bid price below $1.00 for 30 consecutive business days (Aug 4 to Sep 15).
-
XBP Global Q2 revenue up 17.8% YoY, completes BPA acquisition eliminating $1.1B debt
Q2 revenue $39.6M (+17.8% YoY); gross margin 29.8% (+1020 bps); Adj. EBITDA $3.3M (+173.8% YoY).
-
XBP emerges from restructuring; issues 81.8M shares to noteholders, new board and $150M ABL facility
Issued 81,799,821 shares of common stock to allowed note claims; total outstanding 117,516,255 shares.
-
XBP Europe completes acquisition of Exela BPA; combined revenue >$900M, eliminates $1.1B debt
Acquisition of Exela Technologies BPA closed, resulting in combined company with over $900M annual revenue and ~11,000 employees across 19 countries.
-
XBP Europe Q1 revenue $37.7M, Adj EBITDA $3.7M (+25.6% YoY), net loss $3.9M due to stock comp
Revenue $37.7M, down 1.2% YoY but up 5.7% sequentially; gross margin 30.1% (+380 bps YoY).
-
XBP Europe regains Nasdaq compliance; listing continues on Capital Market
Received notice from Nasdaq Hearings Panel confirming compliance with Listing Rule 5550(b)(2) (minimum $35M market value of listed securities).
-
XBP Europe FY24 revenue $142.8M (-8% YoY); operating profit up to $3.5M; signs LOI for Exela BPA
Full-year revenue $142.8M, down 8.0% YoY; gross margin improved 110 bps to 26.8%.
-
XBP Europe Q3 revenue down 5.6% YoY but adjusted EBITDA jumps 116% to $4.8M
Revenue of $35.4M (-5.6% YoY); Bills & Payments $24.6M (-3.1%), Technology $10.8M (-10.8%).
-
XBP Europe receives Nasdaq delisting determination for MVPHS non-compliance; hearing requested
Nasdaq notified XBP Europe on Oct 18, 2024 that it fails MVPHS ($15M minimum) for continued listing on Nasdaq Global Market.
-
On Aug 30, 2024, Nasdaq notified XBP that its MVLS was below $50M minimum for 30 consecutive days.
-
XBP Europe Q2 2024 revenue falls 14.8% to $36.1M; net loss widens to $4.7M
Revenue of $36.1M, down 14.8% YoY; net loss of $4.7M vs $0.6M loss in 2Q 2023.
-
XBP Europe completes $48M financing with HSBC, including $33M incremental liquidity
New Facilities Agreement with HSBC: Term Loan A (£3M), Term Loan B (€10.5M), Revolving Credit Facility (£12M), plus accordion up to $18M.
-
XBP Europe stockholders approve 2024 equity plan, set exec compensation details
Plan authorizes up to 5,520,270 shares of common stock for equity awards.
-
XBP Europe Q1 revenue down 5.7% to $40.4M; net loss narrows; wins $40M HMPO contract
Revenue $40.4M (down 5.7% YoY); gross margin improved to 24.6% (+250 bps YoY).
-
XBP Europe receives Nasdaq deficiency notice for MVPHS below $15M
On April 19, 2024, Nasdaq notified XBP that MVPHS had been under $15M for 30 consecutive business days.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.70 · Most common event earnings